Menglin Bai

发表

Efficacy of Immune Checkpoint Inhibitors in Patients With EGFR Mutated NSCLC and Potential Risk Factors Associated With Prognosis: A Single Institution Experience

Weiqing Wang, Jinming Yu, Leilei Wu, 2022, Frontiers in Immunology.

Negative Correlation Between 18F-RGD Uptake via PET and Tumoral PD-L1 Expression in Non-Small Cell Lung Cancer

Jingru Liu, Min Wu, Xue Meng, 2022, Frontiers in Endocrinology.

Tumor metabolic and secondary lymphoid organ metabolic markers on 18F-fludeoxyglucose positron emission tomography predict prognosis of immune checkpoint inhibitors in advanced lung cancer

Xue Meng, Menglin Bai, Jinming Yu, 2022, Frontiers in Immunology.

PET/CT metabolic patterns in systemic immune activation: A new perspective on the assessment of immunotherapy response and efficacy.

Jinming Yu, Xue Meng, Leilei Wu, 2021, Cancer letters.

Comparison of two detection systems for circulating tumor cells among patients with renal cell carcinoma

Yang Ou, Sheng Li, Menglin Bai, 2018, International Urology and Nephrology.

Radiation combined with immune checkpoint inhibitors for unresectable locally advanced non-small cell lung cancer: synergistic mechanisms, current state, challenges, and orientations

Ya-ping Xu, Leilei Wu, Menglin Bai, 2023, Cell Communication and Signaling.

TPPP3 Promotes Cell Proliferation, Invasion and Tumor Metastasis via STAT3/ Twist1 Pathway in Non-Small-Cell Lung Carcinoma

Jinming Yu, Naijia Liu, Menglin Bai, 2018, Cellular Physiology and Biochemistry.

Integrated analysis of EGFR mutated non‐small cell lung cancer reveals two distinct molecular subtypes

Hao Chen, Leilei Wu, Menglin Bai, 2023, Clinical and translational medicine.

PARP inhibitor plus radiotherapy reshape the immune suppressive microenvironment and potentiate the efficacy of immune checkpoint inhibitors in tumors with IDH1 mutation.

Menglin Bai, Xiaoyu Hu, Jinming Yu, 2024, Cancer letters.